title: Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial".
authors.forename: Richard G
authors.initials: RG
authors.lastname: Stevens
authors.forename: Theresa P
authors.initials: TP
authors.lastname: Pretlow
authors.forename: D Paul
authors.initials: DP
authors.lastname: Hurlstone
authors.forename: Charles
authors.initials: C
authors.lastname: Giardina
authors.forename: Daniel W
authors.initials: DW
authors.lastname: Rosenberg
mesh_terms: D000236:Adenoma / Q000175:diagnosis / Q000473:pathology / Q000517:prevention & control*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis; D000068579:Celecoxib; D018890:Chemoprevention / Q000379:methods; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000517:prevention & control*; D032921:Consensus; D055088:Early Detection of Cancer; D006801:Humans; D007413:Intestinal Mucosa / Q000473:pathology*; D011230:Precancerous Conditions / Q000175:diagnosis* / Q000473:pathology; D011720:Pyrazoles / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib